


FORM PTO - 1449

THIRD SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/621,268

FILING DATE: July 21, 2000 GROUP: 1642

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
KAC	A75	4,703,008	10/27/87	Lin			
	A76	5,441,868	8/15/95	Lin			
	A77	5,457,038	10/10/95	Trinchieri <i>et al.</i>			
	A78	5,547,933	8/20/96	Lin			
	A79	5,618,698	4/8/97	Lin			
	A80	5,688,679	11/18/97	Powell			
	A81	5,756,349	5/26/98	Lin			
	A82	5,955,422	9/21/99	Lin			
	A83	6,231,536	5/15/01	Lentz			
	A84	6,284,536	9/4/01	Morrison <i>et al.</i>			
	A85	6,340,742	1/22/02	Burg <i>et al.</i>			
	A86	6,506,405	1/14/03	Desai <i>et al.</i>			
	A87	6,583,272	6/24/03	Bailon			
	A88	6,586,398	7/1/03	Kinstler <i>et al.</i>			
	A89	2002/0142374	10/3/02	Gallo <i>et al.</i>			
	A90	2003/0003529	1/2/03	Bayer			
✓	A91	2003/0012789	1/6/03	Blumberg <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
KAC	B105	WO 00/24893	5/4/00	PCT					

EXAM. INIT. OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)


KAC	C180	Becker <i>et al.</i> , (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <i>J Clin Invest.</i> , 98(12):2801-2804.
	C181	Becker <i>et al.</i> , (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <i>J Exp. Med.</i> , 183(50):2361-6.
✓	C182	Briggs <i>et al.</i> , (1974), "Hepatic Clearance of Intact and desialylated Erythropoietin," <i>American Journal of Physiology</i> , 227(6):1385-1388.

EXAMINER

DATE CONSIDERED

11/29/05

FORM PTO - 1449

THIRD SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/621,268

FILING DATE: July 21, 2000 GROUP: 1642


U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
KAL		C183		Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291.			
		C184		Cruse et al., (1995), <u>Illustrated Dictionary of Immunology</u> , CRC Press, NY, p.156-7.			
		C185		Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308.			
		C186		Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin Cancer Res.</u> , 4(10):2551-7.			
		C187		Duncan et al., (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740.			
		C188		Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16:3-13.			
		C189		Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502.			
		C190		Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80:317-33.			
		C191		Gan et al., (1999), "Specific enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clin. Diagn. Lab. Immunol.</u> , 6(2):236-42.			
		C192		Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56.			
		C193		Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60.			
		C194		Gillies et al., (2002), "Improved Circulating Half-life and eRfficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Res.</u> , 8(1):210-6.			
		C195		Greene et al., (1975), Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927.			
		C196		Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Res.</u> , 2(12):1951-9.			
		C197		Hank et al., (2003), "Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine," <u>Methods Mol. Med.</u> , 85:123-31.			
		C198		Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 α -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-9.			
		C199		Harris, (1995), "Processing of C-terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," <u>J. Chromatogr. A</u> , 705:129-134.			
✓		C200		Hezareh et al, (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virol.</u> , 75(24):12161-8.			
EXAMINER				DATE CONSIDERED	11/29/05		

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-007					
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies <i>et al.</i>					
		SERIAL NO.: 09/621,268					
		FILING DATE: July 21, 2000 GROUP: 1642					
REPRESENT DOCUMENTS							
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
KAC	C201		Idusogie et al., (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunol.</u> , 164(8):4178-4184.				
	C202		Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Res.</u> , 61(4):1500-7.				
	C203		Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527.				
	C204		Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26:126-131.				
	C205		Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal-macrophage-colony-stimulating Factor for Neuroblastoma," <u>J. Clin. Oncol.</u> , 19:4189-94.				
	C206		Lode et al., (1997), "Targeted interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J Natl Cancer Inst.</u> , 89(21):1586-94.				
	C207		Lode et al., (2000), "What to do with Targeted IL-2," <u>Drugs Today</u> , 36(5):321-36.				
	C208		Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30.				
	C209		Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17:66-70.				
	C210		Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73.				
	C211		Mueller et al. (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452.				
	C212		Mullins et al. (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28.				
	C213		Naramura et al., "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein against Human Melanoma Cells," <u>Immunology Letters</u> , 39(1):91-9.				
	C214		Neal et al. (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol Immunother.</u> , 53:41-52.				
	C215		Ngo et al., (1994), "The Protein Folding Problem and Tertiary Structure Prediction," pp. 433-440 and 492-495, Birkhauser Boston.				
✓	C216		Niethammer et al., (2002) "An oral DNA Vaccine against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-9.				
EXAMINER			DATE CONSIDERED				

FORM PTO - 1449		ATTORNEY DOCKET NO.: LEX-007					
THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies <i>et al.</i>					
		SERIAL NO.: 09/621,268					
		FILING DATE: July 21, 2000 GROUP: 1642					
U.S. PATENT DOCUMENTS							
EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
KAL	C217		Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma," <u>Cancer Research</u> , 61(16):6178-84.				
	C218		Nimtz et al., (1993) Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56.				
	C219		Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92.				
	C220		Park et al., (2000), "Efficiency of Promoter and Cell line in High-level Expression of Erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172.				
	C221		Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J Clin Lab Anal.</u> , 10(3):160-6.				
	C222		Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic nu/nu Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Res.</u> , 56(8):1707-12.				
	C223		Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Res.</u> , 61(23):8498-503.				
	C224		Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30.				
	C225		Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93:1204-1214.				
	C226		Shinkawa et al., (2003), "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473.				
	C227		Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," <u>Therapeutic Immunology</u> , Blackwell Science, Chapter 36, pp. 451-456.				
	C228		Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004.				
	C229		Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517.				
	C230		Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925.				
	C231		Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunol.</u> , 163(7):3676-83.				
	C232		Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J Immunol.</u> , 167(8):4560-5.				
EXAMINER	[Signature]			DATE CONSIDERED 11/29/05			

FORM PTO - 1449

THIRD SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-007

APPLICANT(S): Gillies *et al.*

SERIAL NO.: 09/621,268

FILING DATE: July 21, 2000 GROUP: 1642

U.S. PATENT DOCUMENTS

EXAM. INIT.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
KAC	C233		Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clin Cancer Res.</u> , 7(3 Supp):S856-S864.			
I	C234		Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clin. Oncol.</u> , 16(6):2169-80.			
✓	C235		Zagozdzon et al. (1999), "Potentiation of Antitumor Effect of IL-12 in Combination with Paclitaxel in Murine Melanoma Model In Vivo," <u>International Journal of Molecular Medicine</u> , 4:645-648.			
EXAMINER <i>[Signature]</i>			DATE CONSIDERED 11/29/05			

3030550_1